Johnson & Johnson announced that it has entered into a definitive agreement to acquire Firefly Bio, a biotechnology company developing a proprietary degrader antibody conjugate platform, for $1 billion in cash. The acquisition strengthens Johnson & Johnson’s oncology pipeline and expands its efforts to develop targeted therapies for difficult-to-treat solid tumors driven by KRAS mutations.
At the center of the acquisition is Firefly Bio’s Firelink™ degrader antibody conjugate (DAC) platform, a novel approach designed to deliver highly selective protein degraders directly to tumor cells while minimizing exposure to healthy tissue. The technology is intended to address limitations associated with existing cancer treatments and provide a new therapeutic strategy for cancers that have historically been difficult to target.
KRAS mutations are among the most common cancer-driving genetic alterations and have long been considered challenging drug targets. Despite recent advances, patients with KRAS-driven cancers often face limited treatment options and poor survival outcomes. Johnson & Johnson believes Firefly Bio’s platform could help address these unmet medical needs through a new generation of targeted therapies.
The acquisition also complements Johnson & Johnson’s existing capabilities in antibody engineering and oncology drug development. The company said Firefly Bio’s expertise in emerging therapeutic modalities aligns with its broader strategy of advancing innovative cancer treatments that are more effective, durable, and precise.
For more than 30 years, Johnson & Johnson has invested in oncology research and development, building a portfolio of therapies designed to improve outcomes for cancer patients worldwide. The addition of Firefly Bio’s preclinical programs further diversifies the company’s pipeline and expands its presence in next-generation targeted therapeutics.
Under the terms of the agreement, Johnson & Johnson will acquire Firefly Bio for $1 billion in cash. The transaction is expected to close later in 2026, subject to regulatory approvals and customary closing conditions.
KEY QUOTE:
“KRAS has notoriously been considered an undruggable target and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years. We believe the proprietary Firelink™ platform will overcome the limitations of current treatments and diversify our pipeline with preclinical candidates for treating multiple types of solid tumors.”
John Reed, M.D., Ph.D., Executive Vice President, Innovative Medicine, Research & Development, Johnson & Johnson
